PopulationsHumans

GLP-1 Receptor Agonists and Cardiovascular Events in Adults with Obesity and Autoimmune Disease: A Target Trial Emulation

ADA Scientific Sessions 2026 Abstract

The paper

DAI H, AN LEE Y, NATALIE AS et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 2199-P

doi.org/10.2337/db26-2199-p

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026